Literature DB >> 20004265

Immunization with the attenuated plasmidless Chlamydia trachomatis L2(25667R) strain provides partial protection in a murine model of female genitourinary tract infection.

Norma Olivares-Zavaleta1, William Whitmire, Donald Gardner, Harlan D Caldwell.   

Abstract

Here we report on the safety, immunogenicity, and vaccine efficacy of the naturally occurring plasmid-free attenuated Chlamydia trachomatis L2-25667R (L2R) strain in a murine infection model. Intravaginal immunization induced both chlamydial specific serum antibody and systemic CD4(+) Th1 biased immune responses but failed to induce local IgA antibodies. Immunization induced no pathological changes in the urogenital tract. Protective immunity was evaluated by vaginal challenge with a natural occurring non-attenuated plasmid positive C. trachomatis urogenital strain (serovar D). Vaccinated mice were not protected from colonization/infection but exhibited a reduction in infectious burden at early time periods (1-2 weeks) post-challenge. Partial protective immunity did not protect against inflammatory disease. Thus, intravaginal vaccination with the live-attenuated L2R stain is safe, induces a systemic antibody and CD4(+) Th1 biased immune response, but its protective efficacy is limited to reducing chlamydial burden at early time periods post-infection. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004265      PMCID: PMC2821993          DOI: 10.1016/j.vaccine.2009.11.073

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  24 in total

1.  Intranasal vaccination with a secreted chlamydial protein enhances resolution of genital Chlamydia muridarum infection, protects against oviduct pathology, and is highly dependent upon endogenous gamma interferon production.

Authors:  Ashlesh K Murthy; James P Chambers; Patricia A Meier; Guangming Zhong; Bernard P Arulanandam
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

2.  The original sin of killer T cells.

Authors:  A J McMichael
Journal:  Nature       Date:  1998-07-30       Impact factor: 49.962

3.  Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria.

Authors:  Sukumar Pal; Ellena M Peterson; Luis M de la Maza
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 4.  Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine.

Authors:  Robert C Brunham; José Rey-Ladino
Journal:  Nat Rev Immunol       Date:  2005-02       Impact factor: 53.106

5.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

6.  The Chlamydia trachomatis plasmid is a transcriptional regulator of chromosomal genes and a virulence factor.

Authors:  John H Carlson; William M Whitmire; Deborah D Crane; Luke Wicke; Kimmo Virtaneva; Daniel E Sturdevant; John J Kupko; Stephen F Porcella; Neysha Martinez-Orengo; Robert A Heinzen; Laszlo Kari; Harlan D Caldwell
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

7.  Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against chlamydial genital tract infection.

Authors:  H Su; M Parnell; H D Caldwell
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

8.  Plasmid-deficient Chlamydia muridarum fail to induce immune pathology and protect against oviduct disease.

Authors:  Catherine M O'Connell; Robin R Ingalls; Charles W Andrews; Amy M Scurlock; Toni Darville
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

9.  Differential CD28 and inducible costimulatory molecule signaling requirements for protective CD4+ T-cell-mediated immunity against genital tract Chlamydia trachomatis infection.

Authors:  Ellen Marks; Martina Verolin; Anneli Stensson; Nils Lycke
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

10.  Structural and functional analyses of the major outer membrane protein of Chlamydia trachomatis.

Authors:  Guifeng Sun; Sukumar Pal; Annahita K Sarcon; Soyoun Kim; Etsuko Sugawara; Hiroshi Nikaido; Melanie J Cocco; Ellena M Peterson; Luis M de la Maza
Journal:  J Bacteriol       Date:  2007-06-29       Impact factor: 3.490

View more
  25 in total

Review 1.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Mapping immunodominant antigens and H-2-linked antibody responses in mice urogenitally infected with Chlamydia muridarum.

Authors:  Hao Zeng; Shuping Hou; Siqi Gong; Xiaohua Dong; Quanming Zou; Guangming Zhong
Journal:  Microbes Infect       Date:  2012-03-03       Impact factor: 2.700

3.  Chlamydia trachomatis plasmid-encoded Pgp4 is a transcriptional regulator of virulence-associated genes.

Authors:  Lihua Song; John H Carlson; William M Whitmire; Laszlo Kari; Kimmo Virtaneva; Daniel E Sturdevant; Heather Watkins; Bing Zhou; Gail L Sturdevant; Stephen F Porcella; Grant McClarty; Harlan D Caldwell
Journal:  Infect Immun       Date:  2013-01-14       Impact factor: 3.441

Review 4.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 5.  Emancipating Chlamydia: Advances in the Genetic Manipulation of a Recalcitrant Intracellular Pathogen.

Authors:  Robert J Bastidas; Raphael H Valdivia
Journal:  Microbiol Mol Biol Rev       Date:  2016-03-30       Impact factor: 11.056

6.  Plasmid CDS5 influences infectivity and virulence in a mouse model of Chlamydia trachomatis urogenital infection.

Authors:  K H Ramsey; J H Schripsema; B J Smith; Y Wang; B C Jham; K P O'Hagan; N R Thomson; A K Murthy; R J Skilton; P Chu; I N Clarke
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

7.  Identification of antigen-specific antibody responses associated with upper genital tract pathology in mice infected with Chlamydia muridarum.

Authors:  Hao Zeng; Siqi Gong; Shuping Hou; Quanming Zou; Guangming Zhong
Journal:  Infect Immun       Date:  2011-12-12       Impact factor: 3.441

Review 8.  Update on Chlamydia trachomatis Vaccinology.

Authors:  Luis M de la Maza; Guangming Zhong; Robert C Brunham
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

9.  Murine Chlamydia trachomatis genital infection is unaltered by depletion of CD4+ T cells and diminished adaptive immunity.

Authors:  Sandra G Morrison; Christina M Farris; Gail L Sturdevant; William M Whitmire; Richard P Morrison
Journal:  J Infect Dis       Date:  2011-02-14       Impact factor: 5.226

10.  Prevention of Chlamydia-induced infertility by inhibition of local caspase activity.

Authors:  Joseph U Igietseme; Yusuf Omosun; James Partin; Jason Goldstein; Qing He; Kahaliah Joseph; Debra Ellerson; Uzma Ansari; Francis O Eko; Claudiu Bandea; Guangming Zhong; Carolyn M Black
Journal:  J Infect Dis       Date:  2013-01-09       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.